Doctor of Podiatric Medicine Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leslie Pyle

Podiatrist, Foot & Ankle Surgery Ames, IA Doctor of Podiatric Medicine

NPI 1568950970 CMS profile 11283773

1215 Duff Ave, Ames, IA 50010

Open in the dashboard

General payments

$9,003

114 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leslie Pyle of Ames, IA is reported in the CMS Open Payments database as having received $9,003 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,012 35
2024 General $727 20
2023 General $1,504 23
2022 General $2,297 31
2021 General $2,462 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leslie Pyle
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Leslie Pyle were reported at $2,012. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Leslie Pyle Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $0 $389 $118–$1,406 $163
2020 $0 $191 $62–$691 $114
2021 $2,462 $329 $104–$1,341 $132
2022 $2,297 $419 $125–$1,611 $149
2023 $1,504 $377 $128–$1,164 $160
2024 $727 $394 $134–$1,168 $164
2025 $2,012 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Stryker Corporation $5,336 92 payments
  2. Wardlow Enterprises $1,226 2 payments
  3. Pinnacle, Inc $1,225 2 payments
  4. Arthrex, Inc. $448 2 payments
  5. Integra LifeSciences Corporation $361 2 payments
  6. Acera Surgical, Inc. $198 4 payments
  7. Medline Industries, Inc. $59 1 payment
  8. Smith+Nephew, Inc. $54 3 payments
  9. Organogenesis Inc. $30 1 payment
  10. GRT US Holding, Inc. $17 1 payment
  11. Other $48 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $3,656 14 payments
  2. Education $2,599 6 payments
  3. Food and Beverage $2,407 93 payments
  4. Long term medical supply or device loan $341 1 payment
Products named General payments · program years 2021–2025
  1. PRIME SERIES $1,446 6 payments
  2. INBONE $1,390 7 payments
  3. PROSTEP $828 19 payments
  4. SALVATION $463 6 payments
  5. ACell $341 1 payment
  6. INFINITY ADAPTIS $310 10 payments
  7. Restrata Wound Matrix $198 4 payments
  8. INFINITY $148 4 payments
  9. T2 $141 5 payments
  10. PROPHECY $123 4 payments
  11. Other $1,098 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

153

Median for Podiatry: 160

Drug cost

$1,518

Median for Podiatry: $2,368

Branded share of claims

43.1%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 19 $459
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 29 $270
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 12 $251
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 25 $168
Doxycycline Hyclate Generic 20 $160
Methylprednisolone Generic 24 $132
Triamcinolone Acetonide Generic 11 $40
Meloxicam Generic 13 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$95,065

Of which drugs: $164

Medicare patients

433

Average age 76

Services billed

1,603

260 women, 173 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Diabetes 36%
Chronic kidney disease 29%
Ischemic heart disease 25%
Depression 21%
Atrial fibrillation 20%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 33 218 $164

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record